S. Sablayrolles

Protease-Activated Receptor-1 Antagonist F 16618 Reduces Arterial Restenosis by Down-Regulation of Tumor Necrosis Factor α and Matrix Metalloproteinase 7 Expression, Migration, and Proliferation of Vascular Smooth Muscle Cells

S. Hatem, A. Lompré, M. David-Dufilho, 2011, Journal of Pharmacology and Experimental Therapeutics.

3-(R)-[3-(2-Methoxyphenylthio-2-(S)-methylpropyl]amino-3,4-dihydro-2H-1,5-benzoxathiepine Bromhydrate (F 15845) Prevents Ischemia-Induced Heart Remodeling by Reduction of the Intracellular Na+ Overload

Monique Bernard, D. Feuvray, B. Vacher, 2009, Journal of Pharmacology and Experimental Therapeutics.

Protease-Activated Receptor-1 Mediates Thrombin-Induced Persistent Sodium Current in Human Cardiomyocytes

D. Cussac, V. Algalarrondo, S. Hatem, 2008, Molecular Pharmacology.

F 15845, a new blocker of the persistent sodium current prevents consequences of hypoxia in rat femoral artery

A. Bocquet, B. Vacher, B. Le Grand, 2010, British journal of pharmacology.

Effects of a new PAR1 antagonist, F 16618, on smooth muscle cell contraction.

L. de Vries, A. Bocquet, B. Le Grand, 2009, European journal of pharmacology.